US Stocks Show Varied Performance; Riskified Shares Decline Following Q2 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: Benzinga
Market Overview: U.S. stocks showed mixed results, with the Dow and NASDAQ slightly up while the S&P 500 fell by 0.03%.
Sector Performance: Information technology shares increased by 0.3%, whereas energy stocks dropped by 1.1%.
Notable Stock Movements: Riskified shares fell 13% despite meeting earnings expectations, while Propanc Biopharma surged 210% after uplisting to Nasdaq.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.77%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASBP
About ASBP
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. The Company is a developer of multi-faceted patent-pending drug delivery technology. It is engaged in developing and marketing the disruptive technology for novel sublingual delivery mechanisms for known drugs. Its patent pending delivery system includes components formulated to allow sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract. Its delivery technology is focused on different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements. Its Sublingual Aspirin Product addresses cardiology emergencies and pain management. Its other products include Melatonin, Vitamins, Erectile Dysfunction Medication, Caffeine Products, and Other Products, which includes anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Aspire Biopharma Shares Rise Over 6% in Premarket Trading
- Stock Price Surge: Aspire Biopharma Holdings, Inc. (ASBP) shares have risen over 6% in premarket trading, indicating positive market sentiment towards its innovative drug development, particularly in cardiology emergencies and pain management.
- New Drug Application Plans: The company plans to file a New Drug Application (NDA) for its lead candidate Instaprin via the 505(b)(2) pathway by the end of 2026, which could provide a new solution for cardiology emergencies and significantly enhance the company's market competitiveness.
- Share Repurchase Program: Aspire Biopharma announced a $5 million share repurchase program, with the board authorizing the buyback of up to $5 million of common stock, a move that will strengthen the company's financial flexibility and potentially enhance shareholder value.
- Market Performance Volatility: ASBP has traded between $0.16 and $35 over the past year, and although the stock closed at $0.20 on Tuesday, down 14.42% from the previous day, the recent price rebound reflects investor confidence in the company's future prospects.
See More
Aspire Biopharma Expands with $30M Acquisition of Dura Control Systems
- Acquisition Expansion: Aspire Biopharma announced a $30 million all-cash acquisition of global automotive supplier Dura Control Systems, which generates over $200 million in annual revenue and more than $20 million in earnings, thereby enhancing Aspire's competitive position beyond its core biotech business.
- Financing Support: To facilitate this acquisition, Aspire secured a $22.5 million credit facility and stated it does not plan to raise additional equity, demonstrating confidence and flexibility in its capital operations, which will aid future strategic initiatives.
- Share Buyback Plan: The board approved a share repurchase program of up to $5 million, expected to be funded from existing cash, aimed at enhancing shareholder value; the stock surged over 21% on Monday, reflecting positive market sentiment towards the plan.
- Market Sentiment: Retail sentiment on Stocktwits for Aspire Biopharma remains 'bullish', with high message volumes indicating investor expectations for a price rebound, despite some skepticism about the buyback plan's effectiveness, as the stock currently trades around $0.3.
See More
Aspire Biopharma Authorizes $5M Stock Buyback
- Buyback Plan Initiated: Aspire Biopharma's board has authorized a buyback of up to $5 million in common stock, reflecting confidence in the company's balance sheet strength and expected to be funded through existing cash reserves.
- Strategic Acquisition Intent: This buyback authorization complements the recently announced binding letter of intent to acquire Dura Driver Control Systems, indicating potential value creation from the company's drug development pipeline and supplemental business.
- Positive Market Reaction: Following the buyback announcement, Aspire Biopharma's stock price rose 4.68% in premarket trading to $0.2146, showcasing investor optimism regarding the company's future prospects.
- Financing Background: Aspire Biopharma recently secured up to $21 million in convertible preferred stock financing, providing additional financial flexibility for this buyback and further strengthening its capital structure.
See More
Aspire Biopharma Secures $22.5 Million Credit Facility for Acquisition
- Acquisition Financing: Aspire Biopharma secured a $22.5 million credit facility to fund its planned acquisition of Dura Control Systems, which is not expected to require additional equity raises, thereby alleviating financial pressure and enhancing the feasibility of the acquisition.
- Stock Price Rebound: Following the successful close of a $21 million private placement, Aspire Biopharma's shares surged over 20% in pre-market trading, lifting its shareholders' equity above Nasdaq's minimum listing requirement, indicating strong market confidence in its future prospects.
- Retail Market Expansion: Aspire's unit, Buzz Bomb Caffeine Company, partnered with Interwest Brokerage to expand its retail presence in the Intermountain West, a move that will enhance brand visibility and increase sales channels.
- Diversification Strategy: Aspire plans to acquire Dura Control Systems in an all-cash deal valued at $30 million, with DCS projected to generate over $200 million in revenue in FY2025, positioning Aspire to evolve into a diversified, high-revenue business beyond its core drug delivery technology.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Aspire Biopharma Shares Rise Over 6% in Premarket Trading
- Stock Price Surge: Aspire Biopharma Holdings, Inc. (ASBP) shares have risen over 6% in premarket trading, indicating positive market sentiment towards its innovative drug development, particularly in cardiology emergencies and pain management.
- New Drug Application Plans: The company plans to file a New Drug Application (NDA) for its lead candidate Instaprin via the 505(b)(2) pathway by the end of 2026, which could provide a new solution for cardiology emergencies and significantly enhance the company's market competitiveness.
- Share Repurchase Program: Aspire Biopharma announced a $5 million share repurchase program, with the board authorizing the buyback of up to $5 million of common stock, a move that will strengthen the company's financial flexibility and potentially enhance shareholder value.
- Market Performance Volatility: ASBP has traded between $0.16 and $35 over the past year, and although the stock closed at $0.20 on Tuesday, down 14.42% from the previous day, the recent price rebound reflects investor confidence in the company's future prospects.
See More
Aspire Biopharma Expands with $30M Acquisition of Dura Control Systems
- Acquisition Expansion: Aspire Biopharma announced a $30 million all-cash acquisition of global automotive supplier Dura Control Systems, which generates over $200 million in annual revenue and more than $20 million in earnings, thereby enhancing Aspire's competitive position beyond its core biotech business.
- Financing Support: To facilitate this acquisition, Aspire secured a $22.5 million credit facility and stated it does not plan to raise additional equity, demonstrating confidence and flexibility in its capital operations, which will aid future strategic initiatives.
- Share Buyback Plan: The board approved a share repurchase program of up to $5 million, expected to be funded from existing cash, aimed at enhancing shareholder value; the stock surged over 21% on Monday, reflecting positive market sentiment towards the plan.
- Market Sentiment: Retail sentiment on Stocktwits for Aspire Biopharma remains 'bullish', with high message volumes indicating investor expectations for a price rebound, despite some skepticism about the buyback plan's effectiveness, as the stock currently trades around $0.3.
See More
Aspire Biopharma Authorizes $5M Stock Buyback
- Buyback Plan Initiated: Aspire Biopharma's board has authorized a buyback of up to $5 million in common stock, reflecting confidence in the company's balance sheet strength and expected to be funded through existing cash reserves.
- Strategic Acquisition Intent: This buyback authorization complements the recently announced binding letter of intent to acquire Dura Driver Control Systems, indicating potential value creation from the company's drug development pipeline and supplemental business.
- Positive Market Reaction: Following the buyback announcement, Aspire Biopharma's stock price rose 4.68% in premarket trading to $0.2146, showcasing investor optimism regarding the company's future prospects.
- Financing Background: Aspire Biopharma recently secured up to $21 million in convertible preferred stock financing, providing additional financial flexibility for this buyback and further strengthening its capital structure.
See More
Aspire Biopharma Secures $22.5 Million Credit Facility for Acquisition
- Acquisition Financing: Aspire Biopharma secured a $22.5 million credit facility to fund its planned acquisition of Dura Control Systems, which is not expected to require additional equity raises, thereby alleviating financial pressure and enhancing the feasibility of the acquisition.
- Stock Price Rebound: Following the successful close of a $21 million private placement, Aspire Biopharma's shares surged over 20% in pre-market trading, lifting its shareholders' equity above Nasdaq's minimum listing requirement, indicating strong market confidence in its future prospects.
- Retail Market Expansion: Aspire's unit, Buzz Bomb Caffeine Company, partnered with Interwest Brokerage to expand its retail presence in the Intermountain West, a move that will enhance brand visibility and increase sales channels.
- Diversification Strategy: Aspire plans to acquire Dura Control Systems in an all-cash deal valued at $30 million, with DCS projected to generate over $200 million in revenue in FY2025, positioning Aspire to evolve into a diversified, high-revenue business beyond its core drug delivery technology.
See More
